LeonaBio, Inc.
LeonaBio, Inc. (Nasdaq: LONA) is a clinical-stage biopharmaceutical company developing small-molecule therapies for treatment-resistant metastatic breast cancer and neurological diseases. Its lead candidate, lasofoxifene, is a selective estrogen receptor modulator being evaluated with abemaciclib in the Phase 3… From the company’s description.
In fiscal 2025, LeonaBio, Inc. reported a net loss of $105.61M. Operations used $45.73M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What LeonaBio, Inc. does
In the company’s own words
LeonaBio, Inc. (Nasdaq: LONA) is a clinical-stage biopharmaceutical company developing small-molecule therapies for treatment-resistant metastatic breast cancer and neurological diseases. Its lead candidate, lasofoxifene, is a selective estrogen receptor modulator being evaluated with abemaciclib in the Phase 3 ELAINE-3 trial for ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations. LeonaBio acquired global rights to lasofoxifene in December 2025, excluding Asia and certain Middle Eastern countries. The compound was previously approved in Europe as Fablyn for osteoporosis, but is not currently authorized for marketing. Its other clinical-stage candidate, ATH-1105, is an orally available, brain-penetrant small molecule designed to enhance the neurotrophic HGF system and is in development for amyotrophic lateral sclerosis (ALS); the company has completed a Phase 1 trial and is planning a Phase 2 study. LeonaBio also develops ATH-1020, another HGF-system modulator, and early-stage compounds for neurological diseases and other indications. The company’s activities center on drug discovery and clinical development, with no marketed proprietary products.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BOTHELL, WA
- Fiscal year end
- December
- CIK
- 1620463
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns LeonaBio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · LeonaBio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do LeonaBio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of LeonaBio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in LeonaBio, Inc.'s last four quarterly filings that the numbers alone won't show?”